The use of botulinum toxin in pediatric disorders

Physical Medicine and Rehabilitation Clinics of North America

Volumn 14, Issue 4, 2003, Pages 703-725

  Gaebler Spira, Deborah ^a,b   Revivo, Gadi ^c,d  

^a REHABILITATION INSTITUTE OF CHICAGO   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Children's Specialists of San Diego   (United States)

^d RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ACCURACY; CEREBRAL PALSY; CHILD; CHILDHOOD; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG SAFETY; ELECTROMYOGRAM; HUMAN; INCONTINENCE; INTERPERSONAL COMMUNICATION; LIFESPAN; LONG TERM CARE; MEDICAL ASSESSMENT; MEDICAL LITERATURE; MEDICAL SPECIALIST; MOTOR CONTROL; MOTOR PERFORMANCE; MUSCLE CONTRACTURE; MUSCLE FUNCTION; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; NERVE STIMULATION; ORTHOPEDIC SURGERY; PHYSICAL MEDICINE; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; RESEARCH; REVIEW; RHIZOTOMY; SIDE EFFECT; SKILL; SPASTICITY; SURGEON; TRAINING; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0141988828     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-9651(03)00043-3     Document Type: Article

References (117)

1. Boyd RN, Hays RM. Current evidence for the use of botulinum toxin A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 2001;8:1-20.
2. Molnar FE, Sobus KM. Growth and development. In: Molner G, Alexander M, editors. Pediatric rehabilitation. 3rd edition. Philadelphia: Hanley & Belfus; 1999. p. 13-28.
3. Ito JI, Araki A, Tanaka H, et al. Muscle histopathology in spastic cerebral palsy. Brain Dev 1996;18:299-303.
4. Tardieu C, Lespargot A, Tabary C, Bret MD. For how long must the soleus muscle be stretched each day to prevent contracture? Dev Med Child Neurol 1988;30:3-10.
5. Tardieu G, Tardieu C, Colbeau-Justin P, Bret MD. Effects of muscle length on an increased stretch in children with cerebral palsy. J Neurol Neurosurg Psychiatry 1982;45:348-52.
6. Tardieu C, Tabary JC, Tabary C, Huet de la Tour E. Comparison of the sarcomere number adaptation of young and adult animals. J Physiol 1977;73:1045-55.
7. Ziv I, Blackburn N, Rang M, Koreska J. Muscle growth in the normal and spastic muscle. Dev Med Child Neurol 1984;26:94-9.
8. Tardieu C, Tardieu G, Colbeau-Justin P, et al. Trophic muscle regulation in children with congenital cerebral lesions. J Neurol Sci 1979;42:357-64.
9. Tardieu C, Huet de la Tour E, Bret MD, Tardieu G. Muscle hypoextensibility in children with cerebral palsy: I. clinical and experimental observations. Arch Phys Med Rehabil 1982;63:97-107.
10. Shortland AP, Harris CA, Gough M, Robinson RO. Architecture of the medical gastrocnemius in children with spastic diplegia. Dev Med Child Neurol 2002;44:158-63.
11. Booth CM, Cortina-Borja MJ, Theologis TN. Collagen accumulation in muscles of children with cerebral palsy and correlation with severity of spasticity. Dev Med Child Neurol 2001;43:314-20.
12. Bleck EE. Orthopaedic Management in cerebral palsy. Clin Dev Med 1987;129-33.
13. Rang M. Cerebral palsy. In: Morrissy RT, editor. Lovell and Winter's pediatric orthopedics. 3rd edition. Philadelphia: JB Lippincott; 1990. p. 465-506.
14. Cosgrove AP, Graham HK. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse. Dev Med Child Neurol 1994;36:379-85.
15. Graham HK. Botulinum toxin type A management of spasticity in the context of orthopedic surgery for children with spastic cerebral palsy. Eur J Neurol 2001;8:30-9.
16. Graham HK, Aoki KR, Autti-Ramo I, et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 2000;11:67-79.
17. Molenaers G, Desloovere K, Eyssen M, et al. Botulinum toxin type A treatment of cerebral palsy: an integrated approach. Eur J Neurol 1999;6:S51-8.
18. Boyd RN, Graham JEA, Nattrass GR, Graham K. Medium-term response characterization and risk factor analysis of botulinum toxin type A in the management of spasticity in children with cerebral palsy. Eur J Neurol 1999;6:S37-46.
19. Molenaers G, Desloovere K, Eyssen M, et al. A multilevel approach to botulinum toxin type A treatment of the (ilio) psoas in spasticity in cerebral palsy. Eur J Neurol 1999;6:S59-62.
20. Gage JR, Novacheck TF. An update on the treatment of gait problems in cerebral palsy. J Pediatr Orthop Part B 2001;10:265-74.
21. Gage JR. Gait analysis in cerebral palsy. Clin Dev Med 1991;121.
22. Sutherland DH, Kaufman KR, Wayatt MP, et al. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait Posture 1999;10:1-9.
23. Edgar TS. Clinical utility of botulinum toxin in the treatment of cerebral palsy: comprehensive review. J Child Neurol 2001;16:37-46.
24. Scott AB, Kennedy RA, Stubbs HA. Botulinum toxin injection as a treatment for blepharospasm. Arch Opthalmol 1985;103:347-50.
25. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Opthalmol Soc 1981;79:734-70.
26. Stell R, Thompson PD, Marsden CD. Botulinum toxin in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1988;51:920-3.
27. Snow BJ, Tsui JKC, Bhatt MH, et al. Treatment of spasticity with botulinum toxin: a double-blind study. American Neurological Association 1990;28:512-5.
28. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996;46:1306-10.
29. Biedermann RE, Childres MK, Rupright J. Treatment of spastic hypertonia in brain injured patients with botulinum A toxin. Arch Phys Med Rehabil 1993;74:1282.
30. Koman LA, Mooney JF III, Smith B. Neuromuscular blockade in the management of cerebral palsy. J Child Neurol 1996;11(Suppl 1):S23-8.
31. Koman LA, Mooney JF III, Smith B, et al. Management of cerebral palsy with botulinum A toxin: preliminary investigation. J Pediatr Orthop 1993;13:489-95.
32. Koman LA, Mooney JF III, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994;14:299-303.
33. Cosgrove AP, Corry IS, Graham HK. Botulinum toxin in the management of the lower limb in cerebral palsy. Dev Med Child Neurol 1994;36:386-96.
34. Nightingale SL. Unlabeled uses of approved drugs. Drug Inf J 1992;26:141-7.
35. Boyd RN, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. Eur J Neurol 1997;4:S15-22.
36. Molenaers G, Desloovere K, De Cat J. Single event multilevel botulinum toxin type A treatment and surgery: similarities and differences. Eur J Neurol 2001;8:88-97.
37. Corry IS, Cosgrove AP, Duffy CM. Botulinum toxin A compared with stretching casts in the treatment of spastic equinus: a randomized prospective trial. J Pediatr Orthop 1998;18:304-11.
38. Flett PJ, Stern LM, Waddy H, et al. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy. J Pediatr Child Health 1999;35:71-7.
39. Russell D, Rosenbaum P, Cadman DT, Gowland C. The Gross Motor Function Measure: a means to evaluate the effects of physical therapy. Dev Med Child Neurol 1989;31:341-52.
40. Linder M, Schindler G, Michaelis U. Medium-term functional benefits in children with cerebral palsy treated with botulinum toxin type A: 1-year follow-up using Gross Motor Function Measure. Eur J Neurol 2001;8:120-6.
41. Palisano R, Rosenbaum P, Walter S, et al. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol 1997;39:214-23.
42. Rodda J, Graham HK. Classification of gait patterns in spastic hemiplegia and spastic diplegia: a basis for a management algorithm. Eur J Neurol 2001;8:98-108.
43. Boyd RN, Pliatsios V, Starr R, et al. Biomechanical transformation of the gastroc-soleus muscle with botulinum toxin A in children with cerebral palsy. Dev Med Child Neurol 2000;42:32-41.
44. Koman LA, Smith BP, Tingey CT. The effect of botulinum toxin type A injections on the natural history of equinus foot deformity in pediatric cerebral palsy patients. Eur J Neurol 1999;6:S19-22.
45. Thompson NS, Baker RJ, Cosgrove AP, et al. Musculoskeletal modelling in determining the effect of botulinum toxin on the hamstrings of patients with crouch gait. Dev Med Child Neurol 1998;40:622-5.
46. Eames NWA, Baker R, Hill N, et al. The effect of botulinum toxin A on gastrocnemius length: magnitude and duration of response. Dev Med Child Neurol 1999;41:226-32.
47. Goldstein M, Harper D. Management of cerebral palsy: equinus gait. Dev Med Child Neurol 2001;43:563-9.
48. Galli M, Crivellini M, Santambrogio GC, Motta F. Short term effects of "botulinum toxin A" as treatment for children with cerebral palsy: kinematic and kinetic aspects at the ankle joint. Funct Neurol 2001;16:317-23.
49. Massin M, Allington N. Role of exercise testing in the functional assessment of cerebral palsy children after botulinum A toxin injection. J Pediatr Orthop 1999;19:362-5.
50. Corry IS, Cosgrove AP, Duffy CM, et al. Botulinum toxin A in hamstring spasticity. Gait Posture 1999;10:206-10.
51. Chambers HG. Treatment of functional limitations at the knee in ambulatory children with cerebral palsy. Eur J Neurol 2001;8:59-74.
52. Ward AB. Botulinum toxin type A treatment of hip and thigh spasticity: a technique for injection of psoas major muscle. Eur J Neurol 1999;6:S91-3.
53. Willenborg MJ, Shilt JS, Smith BP, et al. Technique for iliopsoas ultrasound-guided active electromyography-directed botulinum A toxin injection in cerebral palsy. J Pediatr Orthop 2002;22:165-8.
54. Cornell MS. The hips in cerebral palsy. Dev Med Child Neurol 1995;37:3-18.
55. Boyd RN, Dobson F, Parrott J. The effect of botulinum toxin type A and a variable hip abduction orthosis on gross motor function: a randomized controlled trial. Eur J Neurol 2001;8:109-19.
56. Heinen F, Linder M, Mall V, et al. Adductor spasticity in children with cerebral palsy and treatment with botulinwn toxin type A: the parents' view of functional outcome. Eur J Neurol 1999;6:S47-50.
57. Koman LA, Mooney JF III, Smith B, et al. Botox Study Group: botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. J Pediatr Orthop 2000;20:108.
58. Gormley ME Jr, Krach LE, Piccini L. Spasticity management in the child with spastic quadriplegia. Eur J Neurol 2001;8:127-35.
59. Koman LA, Gelberman RH, Tob EB, Poehling GG. Cerebral palsy, management of the upper extremity. Clin Orthop 1990;253:62-74.
60. Boyd RN, Morris ME, Graham HK. Management of upper limb dysfunction in children with cerebral palsy: a systematic review. Eur J Neurol 2001;8:150-66.
61. Autti-Ramo I, Larsen A, Taimo A. Management of the upper limb with botulinum toxin type A in children with spastic type cerebral palsy and acquired brain injury: clinical implications. Eur J Neurol 2001;8:136-44.
62. Corry IS, Cosgrove AP, Walsh EG, et al. Botulinum toxin type A in the hemiplegic upper limb: a double-blind trial. Dev Med Child Neurol 1997;39:185-93.
63. Fehlings D, Rang M, Glazier J. An evaluation of botulinum A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy. J Pediatr 2000;137:331-7.
64. Friedman A, Diamond M, Johnston MV, Daffner C. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy. Am J Phys Med Rehabil 2000;79:53-9.
65. Wall SA, Chait LA, Temlett JA, et al. Botulinum A chemodenervation: a new modality in cerebral palsied hands. Br J Plast Surg 1993;46:703-6.
66. Autti-Ramo I, Larsen A, Peltonen J, Von Wendt L. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia. Neuropediatrics 2000;31:4-8.
67. Fehlings D, Rang M, Glazier J, Steele C. Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol 2001;8:145-9.
68. Zancolli EA, Zancolli ER Jr. Surgical management of the hemiplegic spastic hand in cerebral palsy. Surg Clin North Am 1981;61:395.
69. House JH, Gwathmey FW, Fidler MO. A dynamic approach to the thumb-in-palm deformity in cerebral palsy. J Bone Joint Surg 1981;63(2):216-25.
70. Eliasson AC, Ekholm C, Carlstedt T. Hand function in children with cerebral palsy after upper-limb tendon transfer and muscle release. Dev Med Child Neurol 1998;40:612-21.
71. Suskind DL, Tilton A. Clinical study of botulinum A toxin in the treatment of sialorrhea in children with cerebral palsy. Laryngoscope 2002;112:73-81.
72. Lella F, Porta M, San Marco P. Botulinum toxin for the treatment of sialorrhea and drooling in neurological diseases. Gastroenterology 2000;118(4 Suppl 2):A408.
73. Ellies M, Laskawi R, Rohrbach-Volland S. Botulinum toxin to reduce saliva flow: selected indications for ultrasound-guided toxin application into salivary glands. Laryngoscope 2002;112:82-6.
74. Boyd RN, Graham HK. Objective measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J Neurol 1999;6:S23-36.
75. Delgado MR. The use of botulinum toxin type A in children with cerebral palsy: a retrospective study. Eur J Neurol 1999;6:S11-8.
76. Stephens BK, Barkey ME, Hall HR. Techniques to comfort children during stressful procedures. Accid Emerg Nurs 1999;7:226-36.
77. Sparks L. Taking the "ouch" out of injections for children: using distraction to decrease pain. MCN 2001;26:72-8.
78. Bowen AM, Dammeyer MM. Reducing children's immunization distress in a primary care setting. J Pediatr Nurs 1999;14:296-303.
79. Kleiber C, Harper DC. Effects of distraction on children's pain and distress during medical procedures: a meta-analysis. Nurs Res 1999;48:44-9.
80. Abbot K, Fowler-Kerry S. The use of a topical refrigerant anesthetic to reduce the injection pain in children. J Pain Sympt Manage 1995;10:584-90.
81. Gormley ME, Gaebler-Spira D, Delgado MR. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review. J Child Neurol 2001;16:113-8.
82. Francisco GE, Vaughan A, Boake C. Botulinum toxin treatment of upper extremity spasticity: a comparison of two commonly used dilution techniques. Mov Disord 2000;15:47.
83. Yablon SA. Botulinum neurotoxin intramuscular chemodenervation: role in the management of spastic hypertonia and related motor disorders. Phys Med Rehabil Clin N Am 2001;12:833-74.
84. Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double blind study. Arch Phys Med Rehabil 1990;71:24.
85. Graham HK. Botulinum toxin A in cerebral palsy: functional outcomes. J Pediatr 2000;137:300-3.
86. Wissel J, Heinen F, Schenkel A, et al. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: a randomized, double blind study of "high dose" versus "low dose" treatment. Neuropediatrics 1999;30:120-4.
87. Suputtitada A. Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A: preliminary report. Am J Phys Med Rehabil 2000;79:320-6.
88. Russman BS, Tilton A, Gormley ME. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve 1997;6(Suppl):S181-94.
89. Boyd RN, Britton TC, Robinson RO. Transient urinary incontinence after botulinum A toxin [letter]. Lancet 1996;348:481.
90. Bakheit AM, Severa S, Cosgrove A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001;43:234-8.
91. Aoki KR, Guyer B. Botulinum toxin type A and other botulinum toxin stereotypes: a comparative review of biochemical and pharmacological actions. Eur J Neurol 2001;8:21-9.
92. Ajax T, Ross MA, Rodnitzky RL. The role of electromyography in guiding botulinum toxin injections for focal dystonia and spasticity. J Neurol Rehabil 1998;12:1.
93. O'Brien CF. Injection techniques for botulinum toxin using electromyography and electrical stimulation. Muscle Nerve 1997;20:S176.
94. Albany K. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity. Muscle Nerve 1997;20:S221.
95. Desloovere K, Molenaers G, Jonkers I, et al. A randomized study of combined botulinum toxin type A and casting in the ambulant child with cerebral palsy using objective outcome measures. Eur J Neurol 2001;8:75-87.
96. Leach J. Children undergoing treatment with botulinum toxin: the role of the physical therapist. Muscle Nerve 1997;6(Suppl):S194-207.
97. Detrembleur C, Lejune TM, Renders A, Van den Bergh PYK. Botulinum toxin and short term electrical stimulation on the treatment of equinus in cerebral palsy. Mov Disord 2001;17:162-9.
98. Hesse S, Jahnke MT, Luecke D, Mauritz KH. Short term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients. Neurosci Lett 1995;201:37-40.
99. Hesse S, Reiter F, Konrad M, Jahnke MT. Botulinum toxin type A and short term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomized, double blind. Placebo Controlled Trial. Clin Rehabil 1998;12:381.
100. Damiano DL, Quinlivan J, Owen BF, et al. Spasticity versus strength in cerebral palsy: relationships among involuntary resistance, voluntary torque, and motor function. Eur J Neurol 2001;8:40-9.
101. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type a in patients with torticollis. Mov Disord 1994;9:213.
102. Dezfulian M, Bitar R, Bartlett J. Kinetics study of immunological response to clostridium botulinum toxin. J Clin Microbiol 1987;25:1336-7.
103. Doellgast GJ, Beard GA, Bottoms JD, et al. Enzyme-linked immunosorbent assay for detection of clostridium botulinum neurotoxin A, neurotoxin B, and neurotoxin E and solution phase complexes with dual label antibodies. J Clin Microbiol 1994;32:105-111.
104. Doellgast GJ, Triscott MX, Beard GA, et al. Sensitive enzyme-link immunosorbent assay for detection of clostridium botuinum neurotoxins A, B, and E using signal amplification via enzyme-linked coagulation assay. J Clin Microbiol 1993;31:2402-9.
105. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997;6(Suppl):S146-69.
106. Ade-Hall RA, Moore AP. Botulinum toxin A in the treatment of lower limb spasticity in cerebral palsy. Cochrane Database System Rev 2000;(2):CD001408.
107. Denislic M, Meh D. Botulinum toxin in the treatment of cerebral palsy. Neuropediatrics 1995;26:249-52.
108. Blair EM, Love SC, Valentine JP. Proportional change: an additional method of reporting technical and functional outcomes following clinical interventions. Eur J Neurol 2001;8:178-82.
109. Houltram J, Noble I, Boyd RN, et al. Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol 2001;8:194-202.
110. Love SC, Valentine JP, Blair EM, et al. The effect of botulinum toxin type A in the functional ability of the child with spastic hemiplegia: a randomized controlled trial. Eur J Neurol 2001;8:50-8.
111. Mall V, Heinen F, Kirschner J, et al. Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure. J Child Neurol 2000;15:214-7.
112. Reiter F, Danni M, Ceravolo MG. Disability changes after treatment of upper limb spasticity with botulinum toxin. J Nerurol Rehabil 1996;10:47-52.
113. Ubhi T, Bhakta BB, Ives HL, et al. Randomized, double blind, placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy. Arch Dis Child 2000;83:481-7.
114. Wong V. Use of botulinum toxin injection in 17 children with spastic cerebral palsy. Pediatr Neurol 1998;18:124-31.
115. Chambers HG. The surgical treatment of spasticity. Muscle Nerve 1997;6(Suppl):S121-9.
116. Bjornson KF, McLaughlin JF. The measurement of Health-Related Quality of Life (HRQL) in children with cerebral palsy. Eur J Neurol 2001;8:183-93.
117. Boyd RN, Hays RM. Outcome measurement of effectiveness of botulinum toxin type A in children with cerebral palsy: an ICIDH-2 approach. Eur J Neurol 2001;8:167-77.